AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Colgate-Palmolive's Price Target Lowered to $106 by UBS
ByAinvest
Thursday, Jul 17, 2025 11:30 pm ET1min read
UBS lowered its price target on Colgate-Palmolive (CL) to $106 from $109 while maintaining a Buy rating. The move reflects the firm's confidence in the company's performance and growth prospects.
UBS Group has lowered its price target for Colgate-Palmolive (NYSE:CL) to $106 from $109 while maintaining a "Buy" rating on the stock. The move reflects UBS's confidence in Colgate-Palmolive's performance and growth prospects. The new target price suggests a potential upside of 21.45% from the company's previous close [1].Colgate-Palmolive has been the subject of various research reports in recent months. Barclays lifted its target price on the stock from $86 to $87, giving it an "equal weight" rating. Wells Fargo & Company increased its target price from $83 to $88, but assigned an "underweight" rating. JPMorgan Chase & Co. boosted its price target from $95 to $103, giving the stock an "overweight" rating. Citigroup raised its target price from $103 to $108, maintaining a "buy" rating. Piper Sandler reduced its target price from $108 to $107, assigning an "overweight" rating [1].
Colgate-Palmolive's stock has seen mixed reactions from analysts. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $101.00. Institutional investors own 80.41% of the company's stock [1].
Institutional investors have shown interest in Colgate-Palmolive. Westend Capital Management LLC increased its stake in the company by 111.1% during the first quarter. Cornerstone Planning Group LLC raised its holdings by 1,913.3%. Saudi Central Bank, Vermillion Wealth Management Inc., and Bernard Wealth Management Corp. also purchased new stakes in the company [1].
Colgate-Palmolive announced a share repurchase plan on March 20, authorizing the company to repurchase up to $5.00 billion in shares. This move suggests that management believes the stock is undervalued [1].
Colgate-Palmolive operates through two segments: Oral, Personal, and Home Care, and Pet Nutrition. The company reported $0.91 earnings per share for the quarter ending April 25, beating analyst expectations by $0.05. The company's revenue for the quarter was $4.91 billion, down 3.0% year-over-year [1].
References:
[1] https://www.marketbeat.com/instant-alerts/ubs-group-has-lowered-expectations-for-colgate-palmolive-nysecl-stock-price-2025-07-17/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet